Graeme Kelly

Dr. Graeme Kelly

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2016 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
GKGraeme Kelly
Graeme Kelly
AKA. Foltyn-Arfa Kia
A. Foltyn-Arfa Kia
FHF. Hassan
F. Hassan
SOS. O'GRady
S. O'GRady
MMMaria Morgan
Maria Morgan
MDMarc Devocelle
Marc Devocelle
The first targeted anticancer polymeric prodrug candidates of antimicrobial peptides, intended for combination therapy with another polymeric prodrug of an approved antineoplastic agent (doxorubicin) are reported.

17 May 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ÉFÉanna Forde
Éanna Forde
GKGraeme Kelly
Graeme Kelly
LSLouise Sweeney
Louise Sweeney
DFDeirdre Fitzgerald-Hughes
Deirdre Fitzgerald-Hughes
Ronan MacLoughlinRonan MacLoughlin
Ronan MacLoughlin
MDMarc Devocelle
Marc Devocelle
Background: There has been considerable interest in the use of antimicrobial peptides (AMPs) as antimicrobial therapeutics in many conditions including cystic fibrosis (CF). The aim of this study is to determine if the prodrugs of AMPs (pro-AMPs) can be delivered to the lung by a vibrating mesh nebuliser (VMN) and whether the pro-AMP modification has any effect on delivery. Methods: Physical characteristics of the peptides (AMP and pro-AMP) and antimicrobial activity were compared before and after nebulisation. Droplet size distribution was determined by laser diffraction and cascade impaction. Delivery to a model lung was determined in models of spontaneously-breathing and mechanically-ventilated patients. Results: The physical characteristics and antimicrobial activities were unchanged after nebulisation. Mean droplet size diameters were below 5 μm in both determinations, with the fine particle fraction approximately 67% for both peptides. Approximately 25% of the nominal dose was delivered in the spontaneously-breathing model for both peptides, with higher deliveries observed in the mechanically-ventilated model. Delivery times were approximately 170 s per mL for both peptides and the residual volume in the nebuliser was below 10% in nearly all cases. Conclusions: These results demonstrate that the delivery of (pro-)AMPs to the lung using a VMN is feasible and that the prodrug modification is not detrimental. They support the further development of pro-AMPs as therapeutics in CF.

1 May 2023
Verified
Conference Paper
Closed access
Tomás CarrollTomás Carroll
Tomás Carroll
RHR.C. Heeney
R.C. Heeney
IFilaria ferrarotti
ilaria ferrarotti
SOStefania Ottaviani
Stefania Ottaviani
OCO. Cahalane
O. Cahalane
NMN.G. Mcelvaney
N.G. Mcelvaney